Johnson & Johnson Launches First Daily Multifocal Toric Lens with 91% Fit, 95% Clarity
Johnson & Johnson launched ACUVUE OASYS MAX 1-Day MULTIFOCAL for Astigmatism in the UK and Ireland, the first daily disposable multifocal toric lens for presbyopic astigmatic patients. Clinical trials showed 91% first-fit success and 95.3% reporting clear vision, underpinning revenue growth prospects in its vision-care division.
1. Double-Digit Growth Resumes
Johnson & Johnson reported a resurgence in its top‐line momentum over the past twelve months, with overall revenue growth accelerating to 11.3% year-over-year in fiscal 2025, driven primarily by strength in its oncology portfolio. The Janssen immuno-oncology franchise saw sales climb by 24%, while newly launched pipeline therapies contributed $1.2 billion in incremental revenues. Gross margin expansion of 140 basis points reflected higher utilization in manufacturing facilities and favorable product mix, positioning the company to sustain double‐digit revenue growth into 2026 based on its current guidance range of 9%–12%.
2. RBC Capital Raises Price Target
On February 3, RBC Capital affirmed its Outperform rating on Johnson & Johnson and lifted its 12-month price target from $240 to $255, citing improved earnings visibility and a robust product roadmap. The firm highlighted a 52% share-price gain from May 2025 to February 2026, linked to a 3.2% revenue uplift and margin improvements of 90 basis points. RBC’s analysts forecast adjusted EPS of $11.50 for fiscal 2026, up from $10.75 consensus, underpinned by continued cost discipline and operating leverage in medical devices and pharmaceuticals.
3. Stake Reduction by Mediolanum Funds
In its most recent SEC filing for the third quarter of 2025, Mediolanum International Funds Ltd disclosed a 33.1% reduction in its Johnson & Johnson position, selling 140,861 shares and retaining 285,280 shares valued at approximately $51.8 million. This divestiture contrasted with modest additions by other institutions, including a 55% increase by one advisory firm in Q2. Overall, institutional ownership remains high at 69.6%, but the sizeable cut by a prominent fund underscores potential near-term portfolio rebalancing among global asset managers.
4. New Multifocal Toric Lens Launch
Johnson & Johnson recently introduced ACUVUE OASYS MAX 1-Day MULTIFOCAL for ASTIGMATISM in the United Kingdom and Ireland, marking the first daily disposable multifocal toric lens for patients with both astigmatism and presbyopia. Clinical trials demonstrated a 91% first-fit success rate and 95.3% patient satisfaction for clear vision during daily activities. Management anticipates the product will address an unmet need in a market projected to exceed $3.5 billion by 2028, reinforcing the company’s leadership in vision care and supporting mid‐single-digit percentage revenue growth in its medtech segment.